(Q38639264)

English

Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Parkinson's disease

1 reference

based on heuristic

inferred from title

James M. Brophy

object named as

James M Brophy

2

0 references

author name string

Tanja Tran

1

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Samy Suissa

3

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Christel Renoux

4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

19 November 2015

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

985-998

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Clinical practice. Diagnosis and initial management of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinsonʼs Disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Pergolide use in Parkinson disease is associated with cardiac valve regurgitation

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Dopamine agonists and the risk of cardiac-valve regurgitation

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

The frequency of cardiac valvular regurgitation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Bromocriptine use and the risk of valvular heart disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

B-type natriuretic peptide and cardiovalvulopathy in Parkinson disease with dopamine agonist

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Parkinsonism: onset, progression, and mortality

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Risk of heart failure associated with dopamine agonists: a nested case-control study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Fibrotic valvular heart disease subsequent to bromocriptine treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Agonism at 5-HT2B receptors is not a class effect of the ergolines

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Drugs and valvular heart disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Coronary artery disease as the cause of incident heart failure in the population

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Epidemiology, aetiology, and prognosis of heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Dopamine agonist use and the risk of heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Multiple valvular regurgitation associated with bromocriptine therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regression of cardiac valvulopathy related to ergot-derived dopamine agonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dopamine agonist therapy in early Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pergolide associated cardiac valvulopathy based on Ontario administrative data.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40263-015-0293-4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38639264&oldid=2201911501"